Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03201419 · ClinicalTrials.gov registry record · Phase 2
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
NCT03201419 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 302 participants.
The verdict
NCT03201419, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
Study Summary
The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in adults
Interventions
- DRUG Desmopressin
- DRUG Placebo oral solution
- DRUG FE 201836
- DRUG Placebo ODT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2017-07-27 |
| Est. Completion | 2019-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03201419
The ClinicalTrials.gov registry entry for NCT03201419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Desmopressin is the first listed.
NCT03201419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03201419 about?
NCT03201419 is a clinical study titled "A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults". The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in adults
What is the current status of trial NCT03201419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2017-07-27. Estimated completion is 2019-10-31.
What interventions are being tested in trial NCT03201419?
The interventions under investigation include: Desmopressin (DRUG), Placebo oral solution (DRUG), FE 201836 (DRUG), Placebo ODT (DRUG).
Who is sponsoring clinical trial NCT03201419?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.